Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars

2.

The Growing Role of AI in Cancer Treatment

3.

Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma

4.

Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.

5.

Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot